Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
The effect of a six-month treatment with bezafibrate on HDL2 and HDL3, measured as cholesterol and apolipoprotein A-I, was studied in 10 hypertriglyceridemic patients. The significant increase of total HDL-cholesterol and HDL-apolipoprotien A-I was due to an increase of HDL2-cholesterol and HDL2-apolipoprotein A-I. The lowered ratio of cholesterol to apolipoprotein A-I in HDL, HDL2, and HDL3 remained unaltered. It is concluded that bezafibrate raises the possibly antiatherogenic HDL2, whereas the disturbed cholesterol/apolipoprotein A-I ratio is not changed.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008055:Lipids; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate